Yıl: 2022 Cilt: 37 Sayı: 4 Sayfa Aralığı: 426 - 435 Metin Dili: İngilizce DOI: 10.5505/tjo.2022.3701 İndeks Tarihi: 26-05-2023

Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging

Öz:
OBJECTIVE Neoadjuvant chemotherapy (NAC) is applied in locally advanced breast cancers (LABCs). Pathological complete response (PCR) after NAC is associated with prognosis. This prospective study aimed to com- pare the predictive value of semi-quantitative parameters obtained by dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and dual-phase 18F-FDG PET/CT in LABC patients receiving NAC. METHODS Thirty-nine patients with LABC underwent DCE-MRI and 18F-FDG PET/CT at baseline, and 38 after 2-3 cycles of NAC (interim). Tumor diameter, spherical volume (SV), angiographic volume, peak signal intensity (PSI), the rapid and medium component of initial rise, and percentage of Type I, Type II, and Type III curves were calculated. SUVmax, total lesion glycolysis (TLG), and metabolic tumor volume (MTV) were measured using adaptive (adp) and 42% thresholding methods in whole-body and late prone images. Baseline and interim studies calculated percentage changes and compared the surgery results, PCR, and non-PCR. ROC curves were obtained to calculate the area under the curve for PCR prediction. Optimal threshold values to discriminate between PCR and non-PCR were calculated. RESULTS Late prone images had higher sensitivity and specificity to detect the residual tumor (91%, 71.4%) than MRI (84%, 37.5%). 18F-FDG PET/CT parameters differed significantly between PCR and non-PCR groups, except for MTV-42 values. Optimal cutoff values were-65% for SV%, 73% for MTV-adp%, and 88% for TLG-adp%. CONCLUSION Semi-quantitative parameters for 18F-FDG PET/CT and volumetric changes obtained with DCE-MRI can predict response to NAC. Percentage changes in SV, MTV, and TLG can identify non-responding patients better than other parameters.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol 2000;18(7):1558– 69.
  • 2. Fayanju OM, Ren Y, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): A review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg 2018;268(4):591–601.
  • 3. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23(16):3676–85.
  • 4. Imbriaco M, Caprio MG, Limite G, Pace L, De Falco T, Capuano E, et al. Dual-time-point 18F-FDG PET/ CT versus dynamic breast MRI of suspicious breast lesions. AJR Am J Roentgenol 2008;191(5):1323–30.
  • 5. Malhotra A, Tincey S, Naidu V, Papagiorcopulo C, Ghosh D, Tan PH, et al. Characterisation of MRI in- determinate breast lesions using dedicated breast PET and prone FDG PET-CT in patients with breast cancer-a proof-of-concept study. J Pers Med 2020;10(4):148.
  • 6. Abramson RG, Lambert KF, Jones-Jackson LB, Arling- haus LR, Williams J, Abramson VG, et al. Prone versus supine breast FDG-PET/CT for assessing locoregional disease distribution in locally advanced breast cancer. Acad Radiol 2015;22(7):853–9.
  • 7. Fowler AM, Mankoff DA, Joe BN. Imaging neoad- juvant therapy response in breast cancer. Radiology 2017;285(2):358–75.
  • 8. Schmitz AMT, Teixeira SC, Pengel KE, Loo CE, Vo- gel WV, Wesseling J, et al. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F- FDG PET/CT in breast cancer subtypes. PLos One 2017;12(5):e0176782.
  • 9. Gu YL, Pan SM, Ren J, Yang ZX, Jiang GQ. Role of magnetic resonance imaging in detection of patho- logic complete remission in breast cancer patients treated with neoadjuvant chemotherapy: a meta-anal- ysis. Clin Breast Cancer 2017;17(4):245–55.
  • 10. Pahk K, Kim S, Choe JG. Early prediction of patholog- ical complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: com- parison between interim 18F-FDG PET/CT and MRI. Nucl Med Commun 2015;36(9):887–91.
  • 11. Edge SB, Compton CC. The American Joint Commit- tee on Cancer: the 7th edition of the AJCC cancer stag- ing manual and the future of TNM. Ann Surg Oncol 2010;17(6):1471–4.
  • 12. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384(9938):164–72.
  • 13. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonza- lez-Angulo AM, Symmans WF, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemother- apy does not adversely affect patient outcome. J Clin Oncol 2007;25(19):2650–5.
  • 14. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buz- dar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in re- lation to hormone receptor status and other factors. J Clin Oncol 2006;24(7):1037–44.
  • 15. Kupik O, Akin S, Tuncel M, Eren G, Türker A, Kars A, et al. Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lym- phoma: a special emphasis on bone marrow involve- ment. Nucl Med Commun 2020;41:540–9.
  • 16. Moy L, Ponzo F, Noz ME, Maguire GQ Jr, Murphy- Walcott AD, Deans AE, et al. Improving specificity of breast MRI using prone PET and fused MRI and PET 3D volume datasets. J Nucl Med 2007;48(4):528–37.
  • 17. Schillaci O. Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity. Semin Nucl Med 2012;42(4):267–80.
  • 18. Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A, et al. Changes in 18F- FDG tumor metabolism after a first course of neoad- juvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol 2012;23(10):2572–7.
  • 19. Groheux D, Giacchetti S, Hatt M, Marty M, Vercellino L, de Roquancourt A, et al. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemo- therapy predicts the outcome of neoadjuvant treat- ment. Br J Cancer 2013;109(5):1157–64.
  • 20. Andrade WP, Lima EN, Osório CA, do Socorro Maciel M, Baiocchi G, Bitencourt AG, et al. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer? Eur J Surg Oncol 2013;39(12):1358–63.
  • 21. Lee SM, Bae SK, Kim TH, Yoon HK, Jung SJ, Park JS, et al. Value of 18F-FDG PET/CT for early prediction of pathologic response (by residual cancer burden crite- ria) of locally advanced breast cancer to neoadjuvant chemotherapy. Clin Nucl Med 2014;39(10):882–6.
  • 22. Hatt M, Groheux D, Martineau A, Espié M, Hindié E, Giacchetti S, et al. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med 2013;54:341–9.
  • 23. Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, et al. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging- -prospective assessment. Radiology 2012;263(1):53–63.
  • 24. Wang Y, Zhang C, Liu J, Huang G. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat 2012;131(2):357–69.
  • 25. Mghanga FP, Lan X, Bakari KH, Li C, Zhang Y. Fluo- rine-18 fluorodeoxyglucose positron emission tomog- raphy-computed tomography in monitoring the re- sponse of breast cancer to neoadjuvant chemotherapy: a meta-analysis. Clin Breast Cancer 2013;13(4):271–9.
  • 26. Humbert O, Berriolo-Riedinger A, Cochet A, Gau- thier M, Charon-Barra C, Guiu S, et al. Prognostic relevance at 5 years of the early monitoring of neoad- juvant chemotherapy using (18)F-FDG PET in lumi- nal HER2-negative breast cancer. Eur J Nucl Med Mol Imaging 2014;41(3):416–27.
  • 27. Bolouri MS, Elias SG, Wisner DJ, Behr SC, Hawkins RA, Suzuki SA, et al. Triple-negative and non-triple- negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging. Radiology 2013;269(2):354–61.
  • 28. Pengel KE, Koolen BB, Loo CE, Vogel WV, Wesseling J, Lips EH, et al. Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2014;41(8):1515–24.
  • 29. Lim I, Noh WC, Park J, Park JA, Kim HA, Kim EK, et al. The combination of FDG PET and dynamic contrast- enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2014;41(10):1852–60.
  • 30. Bruckmann NM, Morawitz J, Fendler WP, Ruckhäberle E, Bittner AK, Giesel FL, et al. A role of PET/MR in breast cancer? Semin Nucl Med 2022;52(5):611–8.
APA kupik o, Tuncel M, Özgen Kıratlı P, Gülsün Akpınar M, Altundag K, Demirkazık F, Erbas B (2022). Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging. , 426 - 435. 10.5505/tjo.2022.3701
Chicago kupik osman,Tuncel Murat,Özgen Kıratlı Pınar,Gülsün Akpınar Meltem,Altundag Kadri,Demirkazık Figen,Erbas Belkıs Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging. (2022): 426 - 435. 10.5505/tjo.2022.3701
MLA kupik osman,Tuncel Murat,Özgen Kıratlı Pınar,Gülsün Akpınar Meltem,Altundag Kadri,Demirkazık Figen,Erbas Belkıs Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging. , 2022, ss.426 - 435. 10.5505/tjo.2022.3701
AMA kupik o,Tuncel M,Özgen Kıratlı P,Gülsün Akpınar M,Altundag K,Demirkazık F,Erbas B Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging. . 2022; 426 - 435. 10.5505/tjo.2022.3701
Vancouver kupik o,Tuncel M,Özgen Kıratlı P,Gülsün Akpınar M,Altundag K,Demirkazık F,Erbas B Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging. . 2022; 426 - 435. 10.5505/tjo.2022.3701
IEEE kupik o,Tuncel M,Özgen Kıratlı P,Gülsün Akpınar M,Altundag K,Demirkazık F,Erbas B "Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging." , ss.426 - 435, 2022. 10.5505/tjo.2022.3701
ISNAD kupik, osman vd. "Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging". (2022), 426-435. https://doi.org/10.5505/tjo.2022.3701
APA kupik o, Tuncel M, Özgen Kıratlı P, Gülsün Akpınar M, Altundag K, Demirkazık F, Erbas B (2022). Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging. Türk Onkoloji Dergisi, 37(4), 426 - 435. 10.5505/tjo.2022.3701
Chicago kupik osman,Tuncel Murat,Özgen Kıratlı Pınar,Gülsün Akpınar Meltem,Altundag Kadri,Demirkazık Figen,Erbas Belkıs Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging. Türk Onkoloji Dergisi 37, no.4 (2022): 426 - 435. 10.5505/tjo.2022.3701
MLA kupik osman,Tuncel Murat,Özgen Kıratlı Pınar,Gülsün Akpınar Meltem,Altundag Kadri,Demirkazık Figen,Erbas Belkıs Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging. Türk Onkoloji Dergisi, vol.37, no.4, 2022, ss.426 - 435. 10.5505/tjo.2022.3701
AMA kupik o,Tuncel M,Özgen Kıratlı P,Gülsün Akpınar M,Altundag K,Demirkazık F,Erbas B Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging. Türk Onkoloji Dergisi. 2022; 37(4): 426 - 435. 10.5505/tjo.2022.3701
Vancouver kupik o,Tuncel M,Özgen Kıratlı P,Gülsün Akpınar M,Altundag K,Demirkazık F,Erbas B Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging. Türk Onkoloji Dergisi. 2022; 37(4): 426 - 435. 10.5505/tjo.2022.3701
IEEE kupik o,Tuncel M,Özgen Kıratlı P,Gülsün Akpınar M,Altundag K,Demirkazık F,Erbas B "Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging." Türk Onkoloji Dergisi, 37, ss.426 - 435, 2022. 10.5505/tjo.2022.3701
ISNAD kupik, osman vd. "Predictive Value of Dual-phase 18F-FDG PET/CT in the Assessment of Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer: A prospective Comparative Study with Dynamic Contrast-enhanced Magnetic Resonance Imaging". Türk Onkoloji Dergisi 37/4 (2022), 426-435. https://doi.org/10.5505/tjo.2022.3701